Market Closed -
Nasdaq
01:30:00 09/05/2024 am IST
|
5-day change
|
1st Jan Change
|
7.91
USD
|
+0.76%
|
|
+8.65%
|
-20.10%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
-
|
957.8
|
639.3
|
1,010
|
837.9
|
-
|
-
|
Enterprise Value (EV)
1 |
-
|
816.5
|
579.3
|
943.3
|
859.6
|
585.6
|
481.3
|
P/E ratio
|
-2.53
x
|
-11.6
x
|
-5.89
x
|
-9.17
x
|
-6.12
x
|
-5.85
x
|
-5.19
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
25.9
x
|
25.7
x
|
27.6
x
|
27.3
x
|
25.3
x
|
24.8
x
|
EV / Revenue
|
-
|
22
x
|
23.3
x
|
25.8
x
|
28
x
|
17.7
x
|
14.2
x
|
EV / EBITDA
|
-
|
-14.3
x
|
-5.29
x
|
-8.44
x
|
-5.68
x
|
-3.24
x
|
-2.35
x
|
EV / FCF
|
-
|
-
|
-
|
-7.89
x
|
-6.72
x
|
-4.18
x
|
-3.1
x
|
FCF Yield
|
-
|
-
|
-
|
-12.7%
|
-14.9%
|
-23.9%
|
-32.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
-
|
87,546
|
88,177
|
1,01,990
|
1,06,735
|
-
|
-
|
Reference price
2 |
11.44
|
10.94
|
7.250
|
9.900
|
7.850
|
7.850
|
7.850
|
Announcement Date
|
20/04/21
|
28/03/22
|
27/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
37.04
|
24.86
|
36.53
|
30.68
|
33.07
|
33.8
|
EBITDA
1 |
-
|
-57.29
|
-109.5
|
-111.8
|
-151.4
|
-180.8
|
-204.7
|
EBIT
1 |
-
|
-58.19
|
-111.1
|
-114.2
|
-142.2
|
-163.9
|
-191.1
|
Operating Margin
|
-
|
-157.09%
|
-446.79%
|
-312.57%
|
-463.4%
|
-495.44%
|
-565.39%
|
Earnings before Tax (EBT)
1 |
-
|
-57.94
|
-108.1
|
-101.6
|
-132.7
|
-151.3
|
-172.4
|
Net income
1 |
-51.97
|
-58.24
|
-108.2
|
-101.7
|
-132.1
|
-151.6
|
-177.4
|
Net margin
|
-
|
-157.21%
|
-435.14%
|
-278.54%
|
-430.68%
|
-458.51%
|
-524.81%
|
EPS
2 |
-4.530
|
-0.9400
|
-1.230
|
-1.080
|
-1.283
|
-1.342
|
-1.512
|
Free Cash Flow
1 |
-
|
-
|
-
|
-119.5
|
-128
|
-140
|
-155.5
|
FCF margin
|
-
|
-
|
-
|
-327.18%
|
-417.25%
|
-423.3%
|
-460.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/04/21
|
28/03/22
|
27/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
6.787
|
5.716
|
5.758
|
5.771
|
6.92
|
6.411
|
5.766
|
14.6
|
10.73
|
5.431
|
6.471
|
7.836
|
7.668
|
7.693
|
6.25
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-19.57
|
-21.98
|
-25.38
|
-25.2
|
-29.92
|
-30.57
|
-30.29
|
-23.25
|
-25.63
|
-35.01
|
-42.26
|
-34.37
|
-35.9
|
-38.61
|
-34.75
|
Operating Margin
|
-288.33%
|
-384.6%
|
-440.76%
|
-436.7%
|
-432.41%
|
-476.79%
|
-525.25%
|
-159.25%
|
-238.78%
|
-644.69%
|
-652.99%
|
-438.6%
|
-468.15%
|
-501.84%
|
-556%
|
Earnings before Tax (EBT)
1 |
-19.53
|
-21.87
|
-25.21
|
-24.86
|
-29.05
|
-29.01
|
-28.01
|
-20.65
|
-22.24
|
-30.72
|
-37.87
|
-32.48
|
-33.53
|
-35.35
|
-33.51
|
Net income
1 |
-19.59
|
-22.05
|
-25.21
|
-24.86
|
-29.05
|
-29.06
|
-28.01
|
-20.71
|
-22.26
|
-30.76
|
-37.91
|
-32.37
|
-33.34
|
-34.97
|
-33.51
|
Net margin
|
-288.64%
|
-385.69%
|
-437.79%
|
-430.74%
|
-419.8%
|
-453.28%
|
-485.74%
|
-141.87%
|
-207.45%
|
-566.43%
|
-585.91%
|
-413.07%
|
-434.77%
|
-454.54%
|
-536.14%
|
EPS
2 |
-0.2800
|
-0.2600
|
-0.2900
|
-0.2800
|
-0.3300
|
-0.3300
|
-0.3200
|
-0.2300
|
-0.2300
|
-0.3000
|
-0.3500
|
-0.3200
|
-0.3214
|
-0.3314
|
-0.3200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
28/03/22
|
11/05/22
|
10/08/22
|
10/11/22
|
27/03/23
|
09/05/23
|
07/08/23
|
08/11/23
|
18/03/24
|
08/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
21.7
|
-
|
-
|
Net Cash position
1 |
-
|
141
|
60
|
66.4
|
-
|
252
|
357
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.1434
x
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-120
|
-128
|
-140
|
-156
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
7.69
|
1.53
|
3.65
|
4.2
|
5.1
|
Capex / Sales
|
-
|
-
|
30.94%
|
4.18%
|
11.9%
|
12.7%
|
15.09%
|
Announcement Date
|
20/04/21
|
28/03/22
|
27/03/23
|
18/03/24
|
-
|
-
|
-
|
Last Close Price
7.85
USD Average target price
17.57
USD Spread / Average Target +123.84% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.10% | 838M | | +22.56% | 46.4B | | -1.51% | 41.75B | | +48.83% | 41.37B | | -3.42% | 29.71B | | +10.13% | 26.01B | | -20.44% | 19.52B | | +26.45% | 12.43B | | -0.14% | 12.18B | | -0.47% | 12.13B |
Other Biotechnology & Medical Research
|